“New Hope in the Fight Against Deadly Tropical Diseases: DNDi Unveils 2024 Projects of the Year”
By Ayele Addis Ambelu (ayeleradio@gmail.com)
In a major breakthrough for global health, the Drugs for Neglected Diseases initiative (DNDi) has announced its 2024 Projects of the Year, recognizing two groundbreaking innovations that will transform treatment for leishmaniasis and sleeping sickness.
Dr. Laurent Fraisse, Director of R&D at DNDi, celebrated the remarkable progress made by the teams. “These projects highlight the enormous power of partnerships to bring the best science for the most neglected. Together, we can advance scientific discovery and deliver life-saving medical innovations that change lives.”
One of the celebrated projects is DNDI-6899, a promising new compound for leishmaniasis, a deadly parasitic disease that affects millions across Eastern Africa and South Asia. After years of pre-clinical research, this compound is now ready for a Phase I trial. “We are grateful to our partners for advancing this critical early work,” added Fraisse. DNDI-6899 is viewed as a crucial step towards finding a safer, all-oral treatment for the disease, which especially afflicts children.
The second project, fexinidazole, is being hailed as a game-changer in treating T.b. rhodesiense sleeping sickness, the most lethal form of the disease. Thanks to successful clinical trials in Malawi and Uganda, the World Health Organization has approved the drug as the first-line treatment. “We’ve leaped forward in saving lives,” said Fraisse.
With these advancements, DNDi and its partners are making significant strides toward eliminating these devastating diseases, offering hope to millions in the most neglected corners of the world.In a major breakthrough for global health, the Drugs for Neglected Diseases initiative (DNDi) has announced its 2024 Projects of the Year, recognizing two groundbreaking innovations that are set to transform treatment for leishmaniasis and sleeping sickness.
Dr. Laurent Fraisse, Director of R&D at DNDi, celebrated the remarkable progress made by the teams. “These projects highlight the enormous power of partnerships to bring the best science for the most neglected. Together, we can advance scientific discovery and deliver life-saving medical innovations that change lives.”
One of the celebrated projects is DNDI-6899, a promising new compound for leishmaniasis, a deadly parasitic disease that affects millions across Eastern Africa and South Asia. After years of pre-clinical research, this compound is ready for a Phase I trial. “We are grateful to our partners for advancing this critical early work,” added Fraisse. DNDI-6899 is viewed as a crucial step towards finding a safer, all-oral treatment for the disease, which especially afflicts children.
The second project, fexinidazole, is being hailed as a game-changer in treating T.b. rhodesiense sleeping sickness, the most lethal form of the disease. Thanks to successful clinical trials in Malawi and Uganda, the World Health Organization has approved the drug as the first-line treatment. “We’ve leaped forward in saving lives,” said Fraisse.
With these advancements, DNDi and its partners are making significant strides toward eliminating these devastating diseases, offering hope to millions in the most neglected corners of the world.

The graphic illustration by Africa News Channel Magazine, that complements the story, symbolizing the fight against neglected tropical diseases like leishmaniasis and sleeping sickness. It showcases the collaboration between rural healthcare workers and advanced scientific research, reflecting hope and progress.
By Ayele Addis Ambelu (ayeleradio@gmail.com)
